MCID: CTN003
MIFTS: 53

Cutaneous Lupus Erythematosus

Categories: Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Cutaneous Lupus Erythematosus

MalaCards integrated aliases for Cutaneous Lupus Erythematosus:

Name: Cutaneous Lupus Erythematosus 12 77 54 38 15 17
Lupus Erythematosus, Cutaneous 54 74
Lupus Erythematosus Cutaneous 56

Classifications:



External Ids:

Disease Ontology 12 DOID:0050169
KEGG 38 H01595
UMLS 74 C0024137

Summaries for Cutaneous Lupus Erythematosus

Disease Ontology : 12 A lupus erythematosus that causes skin lesions on parts of the body that are exposed to sunlight.

MalaCards based summary : Cutaneous Lupus Erythematosus, also known as lupus erythematosus, cutaneous, is related to subacute cutaneous lupus erythematosus and lupus erythematosus, and has symptoms including pruritus and exanthema. An important gene associated with Cutaneous Lupus Erythematosus is CXCR3 (C-X-C Motif Chemokine Receptor 3), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Hydroxychloroquine and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and lung, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 77 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Cutaneous Lupus Erythematosus

Diseases in the Cutaneous Lupus Erythematosus family:

Subacute Cutaneous Lupus Erythematosus

Diseases related to Cutaneous Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 subacute cutaneous lupus erythematosus 33.9 CD70 EEA1 TNF TRIM21
2 lupus erythematosus 32.1 TNF TREX1 TRIM21
3 vasculitis 30.4 ICAM1 SELE TNF
4 chilblain lupus 1 30.2 MX1 TREX1 TRIM21
5 sialadenitis 30.1 TNF TRIM21
6 sarcoidosis 1 30.0 CXCR3 IL18 TNF
7 lymphadenitis 29.9 CXCR3 ICAM1 IL18 TNF
8 actinic prurigo 29.9 ICAM1 SELE TNF
9 alopecia areata 29.7 GZMB ICAM1 TNF
10 rheumatoid arthritis 29.7 ICAM1 IL17A IL18 SELE TNF
11 erythema multiforme 29.6 CXCR3 GZMB ICAM1 TNF
12 skin disease 29.6 ICAM1 IL17A SELE TNF
13 lichen planus 29.5 CXCR3 GZMB ICAM1 MX1 TNF
14 bronchiolitis obliterans 29.3 CXCR3 GZMB IL17A TNF
15 systemic lupus erythematosus 28.2 CD70 CXCR3 ICAM1 IL17A IL18 MX1
16 lupus erythematosus tumidus 11.9
17 neonatal lupus erythematosus 11.6
18 dermatomyositis 10.4
19 encephalitozoonosis 10.4 MX1 TNF
20 systemic onset juvenile idiopathic arthritis 10.4 IL18 TNF
21 listeria meningitis 10.3 IL18 TNF
22 melanoma metastasis 10.3 IL18 TNF
23 stachybotrys chartarum 10.3 IL18 TNF
24 inflammatory bowel disease 3 10.3 IL18 TNF
25 critical limb ischemia 10.3 SELE TNF
26 scleritis 10.3 SELE TNF
27 diffuse infiltrative lymphocytosis syndrome 10.3 TNF TRIM21
28 retinitis pigmentosa 60 10.3 SELE TNF
29 discoid lupus erythematosus 10.3
30 shwartzman phenomenon 10.3 ICAM1 TNF
31 intermediate uveitis 10.3 CXCR3 TNF
32 orofacial granulomatosis 10.3 CXCR3 TNF
33 trichosporonosis 10.2 IL17A TNF
34 arthus reaction 10.2 ICAM1 TNF
35 heterophyiasis 10.2 ICAM1 SELE
36 phototoxic dermatitis 10.2 ICAM1 TRIM21
37 alopecia 10.2
38 arthritis 10.2
39 psoriasis 10.2
40 lymphocytic vasculitis 10.2 ICAM1 SELE
41 central nervous system vasculitis 10.2 IL17A TNF
42 chronic eosinophilic pneumonia 10.2 CXCR3 ICAM1
43 mooren's ulcer 10.2 ICAM1 SELE
44 hymenolepiasis 10.2 ICAM1 SELE
45 plummer's disease 10.2 ICAM1 SELE
46 subendocardial myocardial infarction 10.2 ICAM1 SELE
47 porphyria cutanea tarda 10.2
48 porphyria 10.2
49 vernal keratoconjunctivitis 10.2 CXCR3 ICAM1
50 autoimmune disease of eyes, ear, nose and throat 10.2 IL17A TNF

Graphical network of the top 20 diseases related to Cutaneous Lupus Erythematosus:



Diseases related to Cutaneous Lupus Erythematosus

Symptoms & Phenotypes for Cutaneous Lupus Erythematosus

UMLS symptoms related to Cutaneous Lupus Erythematosus:


pruritus, exanthema

GenomeRNAi Phenotypes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CD70 GZMB ICAM1 IL17A IL18 MX1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CD70 GZMB ICAM1 IL17A IL18 MX1

MGI Mouse Phenotypes related to Cutaneous Lupus Erythematosus:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.81 CD70 CXCR3 ICAM1 IL17A IL18 SELE
2 digestive/alimentary MP:0005381 9.73 ICAM1 IL17A IL18 KRT15 TNF TREX1
3 homeostasis/metabolism MP:0005376 9.61 CXCR3 ICAM1 IL17A IL18 KRT15 SELE
4 immune system MP:0005387 9.28 CD70 CXCR3 ICAM1 IL17A IL18 SELE

Drugs & Therapeutics for Cutaneous Lupus Erythematosus

Drugs for Cutaneous Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxychloroquine Approved Phase 3,Phase 2 118-42-3 3652
2
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337
3
tannic acid Approved Phase 3,Phase 2 1401-55-4
4
Ustekinumab Approved, Investigational Phase 3 815610-63-0
5 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
6 Antimalarials Phase 3,Phase 2
7 Anti-Infective Agents Phase 3,Phase 2
8 Antiprotozoal Agents Phase 3,Phase 2
9 Antiparasitic Agents Phase 3,Phase 2
10 Radiation-Protective Agents Phase 3,Not Applicable
11 Dermatologic Agents Phase 3,Phase 2,Not Applicable
12 Protective Agents Phase 3,Not Applicable
13 Sunscreening Agents Phase 3,Not Applicable
14
Etanercept Approved, Investigational Phase 2 185243-69-0
15
Tofacitinib Approved, Investigational Phase 1, Phase 2,Early Phase 1 477600-75-2
16
Norflurane Approved, Experimental Phase 2 811-97-2
17
Tacrolimus Approved, Investigational Phase 2,Not Applicable 104987-11-3 6473866 445643 439492
18
Dimethyl fumarate Approved, Investigational Phase 2 624-49-7 5271565 637568
19
Apremilast Approved, Investigational Phase 1, Phase 2 608141-41-9 11561674
20
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
21
Alitretinoin Approved, Investigational Phase 2 5300-03-8 449171 444795
22
Calcium Approved, Nutraceutical Phase 2,Early Phase 1 7440-70-2 271
23
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
27
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
28 Sifalimumab Investigational Phase 2 1006877-41-3, 162635-04-3 23724530
29 Antibodies Phase 1, Phase 2,Phase 2,Early Phase 1
30 Antibodies, Monoclonal Phase 1, Phase 2,Phase 2
31 Immunoglobulins Phase 1, Phase 2,Phase 2,Early Phase 1
32 Immunologic Factors Phase 2,Early Phase 1,Not Applicable
33 Analgesics Phase 2,Phase 1,Not Applicable
34 Immunosuppressive Agents Phase 2,Not Applicable
35 Anti-Inflammatory Agents Phase 2,Phase 1,Not Applicable
36 Gastrointestinal Agents Phase 2
37 Peripheral Nervous System Agents Phase 2,Phase 1,Not Applicable
38 Analgesics, Non-Narcotic Phase 2,Phase 1,Not Applicable
39 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1,Not Applicable
40 Protein Kinase Inhibitors Phase 1, Phase 2,Early Phase 1
41 Calcium, Dietary Phase 2,Early Phase 1
42 Calcineurin Inhibitors Phase 2,Not Applicable
43 Phosphodiesterase Inhibitors Phase 1, Phase 2
44 Phosphodiesterase 5 Inhibitors Phase 1, Phase 2
45 Phosphodiesterase 4 Inhibitors Phase 1, Phase 2
46 Anti-Bacterial Agents Phase 2
47 Angiogenesis Modulating Agents Phase 2,Not Applicable
48 Angiogenesis Inhibitors Phase 2,Not Applicable
49 Vaccines Phase 2
50 Hormones Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion Completed NCT01551069 Phase 3 hydroxychloroquine (Z0188);Placebo
2 Sunscreen RV 2457C in Photoinduced CLE Completed NCT00470912 Phase 3 sunscreen RV 2547C
3 Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus Recruiting NCT03178188 Phase 2, Phase 3
4 A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus Recruiting NCT03517722 Phase 3 Placebo;Ustekinumab (approximately 6 mg/kg);Ustekinumab 90 mg
5 A Study of Baricitinib in Participants With Systemic Lupus Erythematosus Recruiting NCT03616964 Phase 3 Baricitinib;Placebo
6 A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus Recruiting NCT03616912 Phase 3 Baricitinib;Placebo
7 A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) Not yet recruiting NCT03843125 Phase 3 Baricitinib
8 Phase Ib Study of SC Milatuzumab in SLE Unknown status NCT01845740 Phase 1, Phase 2 milatuzumab;Placebo
9 The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus Unknown status NCT00797784 Phase 2 etanercept(Enbrel®)
10 Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser Completed NCT00523588 Phase 2
11 Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus Completed NCT01294774 Phase 2 KRP203 - 1.2mg;Placebo to KRP203 - 1.2 mg
12 To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus Completed NCT01300208 Phase 2 CC-11050
13 Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE) Completed NCT00317681 Phase 2 Tacrolimus ointment
14 Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Completed NCT01352988 Phase 2 Fumaric acid esters
15 Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients Completed NCT00708916 Phase 1, Phase 2 CC-10004
16 Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus Completed NCT02656082 Phase 2 Etanercept
17 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Completed NCT02265744 Phase 2 BMS-931699;Placebo matching BMS-931699
18 A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus Completed NCT01283139 Phase 2
19 A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus Completed NCT02437890 Phase 2
20 Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions Completed NCT01597050 Phase 2 R932333;Placebo
21 Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions Completed NCT00625521 Phase 2 ASF 1096 0.5 % cream applied twice daily;Cream vehicle for ASF 1096 cream applied twice daily
22 Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2) Completed NCT00625157 Phase 2 ASF 1096 0.5 % cream;ASF 1096 placebo cream
23 A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus Completed NCT00001680 Phase 2 Thalidomide
24 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
25 Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Recruiting NCT02847598 Phase 2 BIIB059;Placebo
26 Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus Recruiting NCT03260166 Phase 2 nicotinamide
27 A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) Recruiting NCT02660944 Phase 2 RSLV-132;Placebo
28 Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus Recruiting NCT03288324 Phase 1, Phase 2 Tofacitinib
29 Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus Recruiting NCT03451422 Phase 1, Phase 2 AMG 592;Placebo
30 Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Recruiting NCT03951259 Phase 2 SM934;Placebos
31 An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus Recruiting NCT03252587 Phase 2 BMS-986165
32 A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Recruiting NCT03845517 Phase 2 Placebo;PF-06700841 15 mg;PF-06700841 30 mg;PF-06700841 45 mg
33 A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE) Recruiting NCT02975336 Phase 2 Placebo;M2951;M2951;M2951;M2951
34 Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care Recruiting NCT03371251 Phase 1, Phase 2 BOS161721;Placebo
35 Study of Anti-Malarials in Incomplete Lupus Erythematosus Recruiting NCT03030118 Phase 2 Hydroxychloroquine;Placebo Oral Capsule
36 Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Active, not recruiting NCT03134222 Phase 2 Filgotinib;Lanraplenib;Filgotinib placebo;Lanraplenib placebo
37 A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus Not yet recruiting NCT03866317 Phase 2 Secukinumab
38 Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus. Not yet recruiting NCT03958955 Phase 2 Delgocitinib cream;Delgocitinib cream vehicle
39 Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Terminated NCT01407679 Phase 2 Alitretinoin
40 Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus Terminated NCT01498406 Phase 2
41 TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment Terminated NCT02711813 Phase 2 TAB08
42 A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus Terminated NCT01466725 Phase 2 CC-930;Placebo
43 Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva Terminated NCT00308204 Phase 2 Raptiva (efalizumab)
44 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects Completed NCT02927457 Phase 1 GSK2646264 1%;Placebo
45 A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus Completed NCT01702740 Phase 1 1 mg/kg CNTO 136;4 mg/kg CNTO 136;10 mg/kg CNTO 136;Placebo
46 A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis Recruiting NCT03817424 Phase 1 VIB7734;Placebo
47 A Study of NKTR-358 in Participants With Systemic Lupus Erythematosis (SLE) Recruiting NCT03556007 Phase 1 NKTR-358;Placebo
48 Autologous Polyclonal Tregs for Lupus Active, not recruiting NCT02428309 Phase 1
49 A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus Terminated NCT01470313 Phase 1 PD-0360324;Placebo
50 Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus Terminated NCT01389895 Phase 1 AMG 557;AMG 557 Placebo

Search NIH Clinical Center for Cutaneous Lupus Erythematosus

Genetic Tests for Cutaneous Lupus Erythematosus

Anatomical Context for Cutaneous Lupus Erythematosus

MalaCards organs/tissues related to Cutaneous Lupus Erythematosus:

42
Skin, Heart, Lung, T Cells, Kidney, Breast, Thyroid

Publications for Cutaneous Lupus Erythematosus

Articles related to Cutaneous Lupus Erythematosus:

(show top 50) (show all 896)
# Title Authors Year
1
Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. ( 29669194 )
2019
2
Autoantibody profile and clinical patterns in 619 Italian patients with cutaneous lupus erythematosus. ( 29924416 )
2019
3
Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists. ( 30033560 )
2019
4
Reply to: S2k guideline for treatment of cutaneous lupus erythematosus-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). ( 30098058 )
2019
5
Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus. ( 30227141 )
2019
6
Canine Cutaneous Lupus Erythematosus: Newly Discovered Variants. ( 30227971 )
2019
7
Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations. ( 30243657 )
2019
8
Subacute cutaneous lupus erythematosus triggered by an antiviral treatment combination for hepatitis C virus infection. ( 30394571 )
2019
9
Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. ( 30489484 )
2019
10
Neonatal cutaneous lupus erythematosus. ( 30580253 )
2019
11
Applying the Cutaneous Lupus Erythematosus Disease Area and Severity Index to paediatric cutaneous lupus erythematosus. ( 30604554 )
2019
12
Dapsone: an old drug effective for subacute cutaneous lupus erythematosus. ( 30615176 )
2019
13
Validation and Reliability of a Disease-Specific Quality of Life Measure in Patients with Cutaneous Lupus Erythematosus: CLEQoL. ( 30637718 )
2019
14
Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients. ( 30719729 )
2019
15
Are there distinct clinical and pathological features distinguishing Idiopathic from Drug-Induced Subacute Cutaneous Lupus Erythematosus? A European retrospective multicenter study. ( 30763648 )
2019
16
Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus. ( 30846987 )
2019
17
Chronic Cutaneous Lupus Erythematosus: Depression Burden and Associated Factors. ( 30877492 )
2019
18
Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus. ( 30903869 )
2019
19
Subacute cutaneous lupus erythematosus leukoderma treated with melanocyte-keratinocyte transplantation procedure. ( 30932304 )
2019
20
Delineating the healthy human skin UV response and early induction of interferon pathway in cutaneous lupus erythematosus. ( 30974166 )
2019
21
Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus. ( 30984372 )
2019
22
A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. ( 31025748 )
2019
23
Treatment of exfoliative cutaneous lupus erythematosus in a German shorthaired pointer dog with mycophenolate mofetil. ( 31038261 )
2019
24
A review of the evidence and cost of therapies for cutaneous lupus erythematosus. ( 31042129 )
2019
25
Cutaneous lupus erythematosus patients with a negative antinuclear antibody meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics criteria for systemic lupus erythematosus. ( 31058462 )
2019
26
Coexistence of chronic cutaneous lupus erythematosus and frontal fibrosing alopecia. ( 29723351 )
2018
27
Obliterative Bronchiolitis as a Systemic Manifestation of Cutaneous Lupus Erythematosus. ( 30601199 )
2018
28
The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP). ( 30521827 )
2018
29
The Histopathological Spectrum of Pseudolymphomatous Infiltrates in Cutaneous Lupus Erythematosus. ( 28654469 )
2018
30
Subacute cutaneous lupus erythematosus induced by nivolumab. ( 28726325 )
2018
31
Cutaneous lupus erythematosus: quality of life and related factors in a cohort of 260 patients from A Coruña, Spain. ( 28832955 )
2018
32
High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus. ( 28833566 )
2018
33
Chronic cutaneous lupus erythematosus presenting as atypical acneiform and comedonal plaque: case report and literature review. ( 28857716 )
2018
34
Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus. ( 28862574 )
2018
35
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. ( 28989111 )
2018
36
Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. ( 29061479 )
2018
37
Bizarre appearance of chronic cutaneous lupus erythematosus of face mimicking factitial dermatitis. ( 29224226 )
2018
38
Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib. ( 29307217 )
2018
39
Subacute cutaneous lupus erythematosus: is clopidogrel a trigger? ( 29327459 )
2018
40
Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity. ( 29349515 )
2018
41
Cutaneous lupus erythematosus: clinico-pathologic correlation. ( 29368845 )
2018
42
Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea. ( 29423919 )
2018
43
Subacute cutaneous lupus erythematosus presenting in twins. ( 29436018 )
2018
44
Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study. ( 29496481 )
2018
45
Incremental health care services and expenditures associated with depression among individuals with cutaneous lupus erythematosus (CLE). ( 29514557 )
2018
46
Successful treatment of severe subacute cutaneous lupus erythematosus with rituximab in an adolescent. ( 29570834 )
2018
47
Occupational subacute cutaneous lupus erythematosus caused by outdoor work. ( 29603599 )
2018
48
Cutaneous lupus erythematosus, morphea profunda and psoriasis: A case report. ( 29625815 )
2018
49
The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda. ( 29631513 )
2018
50
Cutaneous lupus erythematosus in dogs: a comprehensive review. ( 29669547 )
2018

Variations for Cutaneous Lupus Erythematosus

Expression for Cutaneous Lupus Erythematosus

Search GEO for disease gene expression data for Cutaneous Lupus Erythematosus.

Pathways for Cutaneous Lupus Erythematosus

Pathways related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 CD70 EEA1 ICAM1 IL17A IL18 MX1
2
Show member pathways
13.06 CD70 ICAM1 IL17A IL18 MX1 TNF
3
Show member pathways
12.65 GZMB ICAM1 IL17A IL18 TNF
4
Show member pathways
12.06 IL17A IL18 MX1 TNF
5 12.03 EEA1 IL18 TNF
6 11.9 ICAM1 SELE TNF
7
Show member pathways
11.87 IL17A IL18 TNF
8 11.78 ICAM1 SELE TNF
9 11.7 ICAM1 SELE TNF
10 11.68 ICAM1 IL17A IL18 TNF
11 11.52 IL17A IL18 TNF
12 11.52 ICAM1 IL17A IL18 TNF
13
Show member pathways
11.45 ICAM1 SELE TNF
14 11.32 ICAM1 IL18 TNF
15 11.15 ICAM1 IL18 SELE TNF
16 11.05 IL17A IL18 TNF
17 11 ICAM1 IL18
18 10.96 CD70 IL17A IL18 TNF
19 10.93 IL18 TNF
20 10.92 CXCR3 GZMB IL17A IL18 TNF
21 10.82 ICAM1 IL18 SELE TNF
22 10.77 ICAM1 TNF

GO Terms for Cutaneous Lupus Erythematosus

Cellular components related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CXCR3 ICAM1 IL17A TNF

Biological processes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.8 CD70 IL17A IL18 TNF
2 leukocyte migration GO:0050900 9.71 ICAM1 SELE TNF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.63 ICAM1 IL18 TNF
4 cytokine-mediated signaling pathway GO:0019221 9.62 ICAM1 IL17A IL18 TNF
5 leukocyte cell-cell adhesion GO:0007159 9.52 ICAM1 SELE
6 negative regulation of myoblast differentiation GO:0045662 9.51 IL18 TNF
7 natural killer cell mediated cytotoxicity GO:0042267 9.48 GZMB IL18
8 positive regulation of osteoclast differentiation GO:0045672 9.43 IL17A TNF
9 leukocyte tethering or rolling GO:0050901 9.4 SELE TNF
10 regulation of type I interferon production GO:0032479 9.37 TREX1 TRIM21
11 immune response GO:0006955 9.35 CD70 CXCR3 IL17A IL18 TNF
12 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.26 ICAM1 TNF
13 positive regulation of neuroinflammatory response GO:0150078 9.16 IL18 TNF
14 inflammatory response GO:0006954 9.02 CXCR3 IL17A IL18 SELE TNF

Molecular functions related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 8.96 CD70 TNF
2 cytokine activity GO:0005125 8.92 CD70 IL17A IL18 TNF

Sources for Cutaneous Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....